Incidence of cardiogenic shock (CS) after acute myocardial infarction (AMI) is around 5–15%.1 , 2 Cardiogenic shock remains the leading cause of death following AMI, with high mortality rates (40–50%) despite early revascularization.1 , 2 Intravenous inotropic agents (like dobutamine) may be considered to increase cardiac output, but this treatment is challenged by temporary circulatory support (TCS).3–5 Temporary mechanical circulatory support after AMI should be now considered for any acute hemodynamic compromise (class of recommendation IIa, level of evidence B or C, for american college of cardiology and american heart association (ACC AHA) 2013 guidelines or european society of cardiology (ESC) 2016 guidelines, respectively).6–8
Micro-impeller (Impella) and peripheral veno-arterial extracorporeal membrane oxygenator (ECMO) are the most used devices.9 , 10 Extracorporeal membrane oxygenation offers a full circulatory support and has been applied in all CS etiologies.11–13 The Impella devices (2.5, CP, or 5.0) are catheter-mounted micro-axial rotary blood pumps, designed for short-term TCS. The Impella device is inserted via a femoral or axillary artery back to the aorta, and the impeller is positioned across the aortic valve. Blood is aspirated in the left ventricular (LV) and expelled into the ascending aorta at flows ranging from 2.5 to 5.0 l/min. Impella provides a selective left heart assistance with LV unloading, which improves myocardial recovery in experimental conditions.14 However, data allowing an evidence-based choice of TCS device are missing, and most publications report TCS use in very heterogeneous population.11–18 There is no randomized controlled study comparing ECMO versus Impella, but such a comparison might not be clinically relevant since the devices are quite different. Indeed, their technical specificities suggest distinct and complementary indications.
Owing to these device characteristics, our heart team used ECMO or Impella as TCS in patients admitted for emergency percutaneous coronary intervention (PCI) for AMI with CS. This work aims therefore at evaluating the relevance of the device selection and the implantation timing.
From January 2009 to April 2015, patients who were admitted to the intensive care unit (ICU) for CS treated with TCS in the context of AMI were retrospectively analyzed. In order to have a homogeneous study population, delayed TCS after AMI (> 72 hours) or after CS onset (> 48 hours), refractory cardiac arrest before TCS, mechanical AMI complication (ventricular septal defect, papillary muscle rupture), aortic valve pathology (stenosis or regurgitation), early surgical revascularization, or a specific condition (septic shock, cardiac surgery, myocardial trauma) were excluded. Moreover, Impella was not implanted in case of mural thrombus in the left ventricle.
Montpellier Academic Hospital institutional review board approved the study, which waived the need for patients’ informed consent because of the retrospective, observational nature of the study.
Acute Myocardial Infarction Management
All patients with AMI, diagnosed according to international recommendations, underwent PCI (see Supplementary Material 1, Supplemental Digital Content, http://links.lww.com/ASAIO/A220). They received antiplatelet therapy and anticoagulation with unfractionated heparin.
Cardiogenic Shock Management
Cardiogenic shock was defined by sustained hypotension and reduced estimated cardiac output (low LV ejection fraction and low Doppler aortic Velocity Time Integral as assessed by experienced echocardiographer) despite adequate intravascular volume on quick echocardiography check (see supplementary material 2, Supplemental Digital Content, http://links.lww.com/ASAIO/A221). Temporary mechanical circulatory support was inserted when aortic Velocity Time Integral was less than 5 cm, left ventricle ejection fraction (EF) < 20%, and E wave of mitral Doppler inflow was more than 1 m/s), either in case of failure of medical treatment including inotropes and vasopressors or in case of very severe cardiac dysfunction at echocardiography, therefore bypassing inotrope treatment.
Device selection resulted from a multidisciplinary agreement between cardiologists, intensivists, and cardiac surgeons (heart team). The indication of each device as first TCS was based on device characteristics and severity of the CS. There was no formal age limit, but patients older than 75 years were eligible to TCS, in the absence of previous morbidity, provided sufficient cardiac recovery was likely.
Extracorporeal membrane oxygenation was inserted through peripheral, percutaneously or surgically femoro-femoral veno-arterial cannulae and was selected in case of very severe, life-threatening CS. The Impella “2.5” and “CP” were inserted percutaneously through femoral artery. Impella 2.5 device was substituted by CP since March 2014 when this model became available in our center. Impella “5.0” required surgical cut down of femoral or axillary artery. Impella devices were selected in less severe CS.
Moreover, in case of LV overload during ECMO (severe pulmonary edema, left heart cavities distension with spontaneous contrast on echocardiography, or loss of left ventricle ejection), LV unloading was provided by Impella or intra-aortic balloon pump (IABP) in case of Impella contraindication. In case of persistent circulatory shock with Impella, including refractory right ventricular (RV) dysfunction despite inhaled nitric oxide, inotrope and vasopressor, assistance upgrading consisted in adding an ECMO.
Temporary mechanical circulatory support was implanted in cathlab or in operating room. For each device, the lower pump flow necessary to maintain adequate tissue perfusion was wanted (meaning SvcO2 > 65% and correction of metabolic acidosis).
The TCS weaning process followed a stepwise decrease of the pump speed with echocardiography, clinical, and biological monitoring. When TCS weaning was not possible, bridging to long-term left ventricular assist device or heart transplantation was considered, provided there was not severe multiorgan failure.
Patient and procedural characteristics were collected retrospectively. Simplified Acute Physiology Score II, Sepsis-related Organ Failure Assessment score were calculated at ICU admission and the ENCOURAGE mortality risk score19 at TCS implantation. The following data were recorded at ICU admission and during first 48 hours of TCS: vasoactive-inotropic score as defined as dose of dobutamine (μg/Kg/min) + (dose of epinephrine [μg/Kg/min] + dose of norepinephrine [μg/Kg/min]) × 100, inotrope score defined as dose of dobutamine (μg/Kg/min) + (dose of epinephrine [μg/Kg/min]) × 10020 , 21 and blood lactate levels.
The main outcome variables included death before or less than 24 hours after TCS removal, cardiac outcome in TCS survivors (cardiac recovery; bridge to left ventricular assist device; bridge to heart transplantation), ICU discharge, hospital discharge, and 6-month mortality rate.
Continuous variables are presented as median (interquartile range) and categorical variables as number (percentage). Paired Wilcoxon tests were used to describe evolution of clinical, biological, and echocardiographic variables during TCS. Based on the first TCS device used, the study population was divided into two groups, ECMO (ECMO-G) and Impella (Impella-G). Group comparison used Wilcoxon rank-sum test and chi-square tests or Fisher exact tests when appropriate. Statistical significance was defined as p < 0.05. Analyses were performed using the R Core Team 2015 (R Foundation for statistical Computing, Vienna, Austria).
During the study period, 88 patients required TCS after AMI, 42 of them met the criteria of early TCS for CS shortly after AMI (Figure 1); 23 patients (55%) were first treated with ECMO (ECMO-G) and 19 (45%) with Impella (Impella-G). There were no significant differences between groups for the management of myocardial infarction (Table 1).
Twenty-one patients (50%) had preserved hemodynamic stability at PCI admission, but 18 of them (86%) developed CS during PCI (Table 2). The treatment included mechanical ventilation (MV) (98%) and inotropic support (76%), but TCS was anticipated in 10 patients (24%) because of threatening hemodynamic collapse. Of note, 24 patients (60%) experienced transient cardiac arrest.
Extracorporeal membrane oxygenation were inserted percutaneously in seven of the 23 patients. Impella support consisted in “5.0” in seven patients (three femoral access, four axillary access), “CP” in seven patients and “2.5” in five patients.
During TCS, devices needed to be combined in 10 patients (24%) (Figures 1 and 2). In the ECMO-G, six patients (26%) needed an LV discharge with Impella and one patient had IABP because of LV thrombus. Insertion of the Impella device was made 20 (8–25) hours after TCS start, for 7.5 (5–13) days and consisted in 2 “2.5” and 4 “5.0”. In the Impella-G, four of the 19 patients (21%), all treated with percutaneous models (three “CP” and one “2.5”), needed additional support with ECMO, including two refractory RV dysfunctions. Extracorporeal membrane oxygenation was initiated 8 (1–15) hours after Impella insertion and maintained for 9 (6–11) days.
Temporary mechanical circulatory support provided rapid improvement of the patients “clinical condition without significant difference between both groups.” Blood lactate level decreased significantly and was normalized at 24 hours reaching 1.8 (1.3–2.7) mmol/L and 1.7 (1.2–2.7) mmol/L for ECMO-G and Impella-G, respectively (p < 0.01, from before TCS implantation in both groups). In the same time, inotrope score decreased significantly and was reduced to almost zero in ECMO-G (1 [0–5]) and Impella-G (0 [0–2]; [p < 0.001, from before TCS implantation in both groups]). Vasoactive-inotrope score decreased significantly in both groups at 48 hours (36 [7–56] and 20 [0–34] for ECMO-G and Impella-G, respectively [p < 0.01, from before TCS implantation in both groups]).
There was no significant difference between groups regarding device complications or mortality in ICU and at 6 months (TABLES 3, 4). However, device dysfunction was reported only with Impella 2.5 (two of five). Six (32%) Impella-G patients were extubated during TCS; TCS duration and ICU stay were similar in both groups.
In both groups, mortality was found lower than the predicted mortality according to the ENCOURAGE score. In the ECMO-G, mortality rate at 30 days was 30% (predicted 72%), and 48% at 6 months (predicted 80%). In the Impella-G, 37% at 30 days (predicted 65%), and 42% at 6 months (predicted 75%).
A switch to Impella alone was made in five of the 10 patients with combined ECMO and Impella. In this subcategory of patients, two died under TCS, one was weaned from both devices at the same time, and two were weaned from Impella before ECMO.
The study shows that, in a homogeneous population of patients admitted for PCI for AMI, the initial TCS, ECMO or Impella can be adapted to the patient clinical condition according to CS severity.
In case of profound CS, ECMO is a safe option and very effective circulatory support,12 , 22 , 23 which justified its preferred used in the most severe patients of the series.9 Contrary to most published cohorts,23 , 24 we excluded ECMO insertion under CPR to avoid the effect of the cardiac arrest itself, which is independently associated with mortality.11 This exclusion may explain a lower incidence of mortality in our series than in other published reports.23 , 24 However, the CS cases were quite severe, even worst in the ECMO-G, as attested by serum lactate, the vasopressor dose, which gave a high ENCOURAGE score. Among the markers of CS severity, a high lactate level seems a strong indicator in favor of ECMO selection. Indeed, 75% of the ECMO patients had a blood lactate level above 4.8 mmol/L. Nevertheless, we observed a lower mortality rate than the predicted value by the ENCOURAGE score. This low mortality rate may result from the very early initiation of the circulatory assistance in the course of the CS.
Impella 5.0 seems an interesting option for more stable conditions.25 It provided adequate blood flow in all cases, without ECMO rescue support. However, the insertion requires a surgical access that may limit its use to specific centers. Conversely, percutaneous Impella provided inadequate circulatory support in 33% patients. These observations are in agreement with previously published data showing that Impella 2.5 may be not efficient enough as circulatory support.16 , 18 Nevertheless, two of the four patients had refractory RV dysfunction, which might have been observed also with Impella 5.0. Therefore, percutaneous Impella can be considered as an adequate first TCS device, keeping ECMO addition as a secondary option. Impella is a less complex technique (nonsurgical approach, no perfusionist needed), therefore theoretically accessible in many cardiac centers without surgery facilities.
A distinctive feature of our report is the association of ECMO and Impella as a backup strategy in 24% patients. These results highlight the need for combining the two devices in selected situations. Impella ensured successful LV unloading in a significant proportion of ECMO patients (26%), as already reported25; ECMO was added for complementary circulatory support in 21% of Impella patients. The device association should be an integral part of any TCS strategy, possibly through a regional health-care networking, in order to fulfill the two conditions that are equally important for improving survival in CS complicating AMI. First, TCS must be implanted before multiple organ failure; second, PCI should not be delayed as it improves long-term survival.26 The challenge is actually to make compatible the two timing constraints.
Early initiation of TCS before PCI may be beneficial in AMI patients because it may enable a complete revascularization, with better outcome.26–28 This improved revascularization could be even more beneficial in patients developing CS after AMI. Elevated LV filling pressures and low coronary blood flow aggravate myocardial ischemia, a high-risk clinical scenario for PCI.10 In our experience, CS during PCI exposes patients to a high risk of refractory cardiac arrest (15% of the whole population of 88 patients in the flowchart, Figure 1). Conversely, a high survival rate has been already reported either with ECMO or Impella when applied before PCI for CS complicating AMI.15–17
In our series, half of the patients were admitted for PCI without CS, and hemodynamic instability occurred in a great proportion in the cathlab (43%), which means that patient selection for TCS before PCI is quite difficult. Further studies are needed to identify cardiogenic “pre-shock” patients, or to find out criteria to anticipate TCS. For these patients, percutaneous Impella could be the preferred option. Of note in our series, percutaneous Impella CP was the easiest device to be inserted, more quickly than ECMO or Impella 5.0. Otherwise, urgent TCS implantation would remain the only possible alternative, during PCI or soon after, with the available device on site, although ECMO is obviously the TCS of reference in very serious conditions, including cardiac arrest.13
The retrospective, single-center nature, and the sample size of this study are important limitations. However, selection of patients receiving TCS for severe CS early after AMI, excluding patients under CPR, offers a homogeneous study population contrary to numerous other series published to date. Moreover, to our knowledge, it is the first study on TCS in AMI undergoing emergent PCI showing the potential indication of mixing various devices.
In conclusion, based on distinctive indications and possible association of devices, ECMO or Impella are quite suitable in AMI with acute CS. However, implantation timing is more crucial than the device choice, especially in emergency. Combination of the two techniques could be stratified in a predefined strategy, according to center competency, device availability, and eventually structured in a networking including primary to tertiary cardiac centers.
1. Aissaoui N, Puymirat E, Tabone X, et al. Improved outcome of cardiogenic shock
at the acute stage of myocardial infarction
: A report from the USIK 1995, USIC 2000, and FAST-MI French nationwide registries. Eur Heart J 2012.33: 2535–2543.
2. Goldberg RJ, Spencer FA, Gore JM, et al. Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock
in patients with acute myocardial infarction
: A population-based perspective. Circulation 2009.119: 1211–1219.
3. Ponikowski P, Voors AA, Cleland JGF, et al; The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology (ESC). Developed with the special contribution of Heart Failure Association (HFA) of the ESC. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2016.37: 2129–2200.
4. Stretch R, Sauer CM, Yuh DD, et al. National trends in the utilization of short-term mechanical circulatory support: Incidence, outcomes, and cost analysis. J Am Coll Cardiol 2014.64: 1407–1415.
5. Van Herck JL, Claeys MJ, De Paep R, et al. Management of cardiogenic shock
complicating acute myocardial infarction
. Eur Heart J Acute Cardiovasc Care 2015.4: 278–297.
6. Steg PG, James SK, et al; Task Force on the management of ST-segment elevation acute myocardial infarction
of the European Society of Cardiology (ESC), ESC guidelines for the management of acute myocardial infarction
in patients presenting with ST-segment elevation. Eur Heart J 2012.33: 2569–2619.
7. O’Gara PT, et al; American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction
: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013.61: e78–140.
8. Windecker S, Kolh P, et al; Authors/Task Force members, 2014 ESC/EACTS guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 2014.35: 2541–2619.
9. Werdan K, Gielen S, Ebelt H, et al. Mechanical circulatory support in cardiogenic shock
. Eur Heart J 2014.35: 156–167.
10. Rihal CS, Naidu SS, Givertz MM, et al; Society for Cardiovascular Angiography and Interventions (SCAI); Heart Failure Society of America (HFSA); Society of Thoracic Surgeons (STS); American Heart Association (AHA), and American College of Cardiology (ACC). 2015 SCAI/ACC/HFSA/STS clinical expert consensus statement on the use of percutaneous mechanical circulatory support devices in cardiovascular care: Endorsed by the American Heart Assocation, the Cardiological Society of India, and Sociedad Latino Americana de Cardiologia Intervencion; Affirmation of Value by the Canadian Association of Interventional Cardiology-Association Canadienne de Cardiologie d’intervention. J Am Coll Cardiol 2015.65: e7–e26.
11. Combes A, Leprince P, Luyt CE, et al. Outcomes and long-term quality-of-life of patients supported by extracorporeal membrane oxygenation
for refractory cardiogenic shock
. Crit Care Med 2008.36: 1404–1411.
12. Guenther S, Theiss HD, Fischer M, et al. Percutaneous extracorporeal life support for patients in therapy refractory cardiogenic shock
: Initial results of an interdisciplinary team. Interact Cardiovasc Thorac Surg 2014.18: 283–291.
13. Esper SA, Bermudez C, Dueweke EJ, et al. Extracorporeal membrane oxygenation
support in acute coronary syndromes complicated by cardiogenic shock
. Catheter Cardiovasc Interv 2015.86(Suppl 1): S45–S50.
14. Wei X, Li T, Hagen B, et al. Short-term mechanical unloading with left ventricular assist devices after acute myocardial infarction
conserves calcium cycling and improves heart function. JACC Cardiovasc Interv 2013.6: 406–415.
15. Sheu JJ, Tsai TH, Lee FY, et al. Early extracorporeal membrane oxygenator-assisted primary percutaneous coronary intervention improved 30-day clinical outcomes in patients with ST-segment elevation myocardial infarction
complicated with profound cardiogenic shock
. Crit Care Med 2010.38: 1810–1817.
16. Engström AE, Cocchieri R, Driessen AH, et al. The Impella 2.5 and 5.0 devices for ST-elevation myocardial infarction
patients presenting with severe and profound cardiogenic shock
: The Academic Medical Center intensive care unit experience. Crit Care Med 2011.39: 2072–2079.
17. O’Neill WW, Schreiber T, Wohns DH, et al. The current use of Impella 2.5 in acute myocardial infarction
complicated by cardiogenic shock
: Results from the USpella registry. J Interv Cardiol 2014.27: 1–11.
18. Lauten A, Engström AE, Jung C, et al. Percutaneous left-ventricular support with the Impella-2.5-assist device in acute cardiogenic shock
: Results of the Impella-EUROSHOCK-registry. Circ Heart Fail 2013.6: 23–30.
19. Muller G, Flecher E, Lebreton G, et al. The ENCOURAGE mortality risk score and analysis of long-term outcomes after VA-ECMO for acute myocardial infarction
with cardiogenic shock
. Intensive Care Med 2016.42: 370–378.
20. Wernovsky G, Wypij D, Jonas RA, et al. Postoperative course and hemodynamic profile after the arterial switch operation in neonates and infants. A comparison of low-flow cardiopulmonary bypass and circulatory arrest. Circulation 1995.92: 2226–2235.
21. Davidson J, Tong S, Hancock H, et al. Prospective validation of the vasoactive-inotropic score and correlation to short-term outcomes in neonates and infants after cardiothoracic surgery. Intensive Care Med 2012.38: 1184–1190.
22. Yancy CW, Jessup M, Bozkurt B, et al; American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013.62: e147–e239.
23. Jaski BE, Ortiz B, Alla KR, et al. A 20-year experience with urgent percutaneous cardiopulmonary bypass for salvage of potential survivors of refractory cardiovascular collapse. J Thorac Cardiovasc Surg 2010.139: 753–7.e1.
24. Chen YS, Lin JW, Yu HY, et al. Cardiopulmonary resuscitation with assisted extracorporeal life-support versus conventional cardiopulmonary resuscitation in adults with in-hospital cardiac arrest: An observational study and propensity analysis. Lancet 2008.372: 554–561.
25. Gaudard P, Mourad M, Eliet J, et al. Management and outcome of patients supported with Impella 5.0 for refractory cardiogenic shock
. Crit Care 2015.19: 363.
26. Mylotte D, Morice M-C, Eltchaninoff H, et al. Primary percutaneous coronary intervention in patients with acute myocardial infarction
, resuscitated cardiac arrest, and cardiogenic shock
: The role of primary multivessel revascularization. JACC Cardiovasc Interv 2013.6: 115–125.
27. Cohen MG, Matthews R, Maini B, et al. Percutaneous left ventricular assist device for high-risk percutaneous coronary interventions: Real-world versus clinical trial experience. Am Heart J 2015.170: 872–879.
28. O’Neill WW, Kleiman NS, Moses J, et al. A prospective, randomized clinical trial of hemodynamic support with Impella 2.5 versus intra-aortic balloon pump in patients undergoing high-risk percutaneous coronary intervention: The PROTECT II study. Circulation 2012.126: 1717–1727.
myocardial infarction; temporary circulatory support; extracorporeal membrane oxygenation; cardiogenic shock
Supplemental Digital Content
Copyright © 2018 by the American Society for Artificial Internal Organs